Probiotic sepsis in preterm neonates—a systematic review

Tithi Kulkarni, Swati Majarikar, Mangesh Deshmukh, Anitha Ananthan, Haribalakrishna Balasubramanian, Anthony Keil, Sanjay Patole

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

Sepsis due to the administered probiotic strain/s is a barrier against adoption of prophylactic probiotic supplementation in preterm infants to reduce the risk of necrotising enterocolitis (NEC ≥ Stage II), all-cause mortality, late-onset sepsis, and feeding intolerance. We aimed to conduct a systematic review for reports of probiotic sepsis in preterm infants (gestation < 37 weeks). Databases including PubMed, Embase, Emcare, Cochrane Central library, and Google Scholar were searched in August 2021 and updated in Jan 2022. Probiotic sepsis was defined as positive blood/CSF culture isolating administered probiotic strain with symptoms suggestive of infection. Data collection included birth weight, gestation, comorbidities (e.g. gut surgery, NEC), presence of central venous catheters, treatment, and outcome. Literature search revealed 1569 studies. A total of 16 reports [randomised control trial (RCT): none; non-RCT: 1; case series: 8; case report: 7] involving 32 preterm infants with probiotic sepsis were included after exclusions for various reasons. Majority of the cases were born < 32 weeks’ gestation. Bifidobacterium (N = 19) was the most commonly isolated organism followed by Lactobacillus (N = 10), and Saccharomyces (N = 3). A total of 25/32 cases were confirmed to be due to the administered probiotic strain on full genomic analysis. Two studies reported one neonatal death each. Twelve neonates had comorbidities. Majority were treated with antibiotics (29/32) whereas others (3/32) required antifungal treatment. Conclusion: Probiotics sepsis is relatively an uncommon event in preterm infants. Majority of the cases recovered after antibiotic or antifungal treatment. The importance of optimal surveillance and treatment of probiotic sepsis and research towards alternatives to probiotics (e.g. postbiotics) is emphasised.What is Known:• Probiotics have been shown to reduce necrotising enterocolitis, late-onset sepsis, all-cause mortality, and time to reach full enteral feeds in preterm infants.• Despite the evidence, use of probiotics is not universal due to concerns regarding probiotic-associated sepsis in preterm infants.What is New:• This comprehensive systematic review showed that probiotic sepsis is a relatively rare phenomenon in preterm infants.• All except one case where the diagnosis was uncertain recovered after antimicrobial therapy.

Original languageEnglish
Pages (from-to)2249-2262
Number of pages14
JournalEuropean Journal of Pediatrics
Volume181
Issue number6
Early online date2022
DOIs
Publication statusPublished - Jun 2022

Fingerprint

Dive into the research topics of 'Probiotic sepsis in preterm neonates—a systematic review'. Together they form a unique fingerprint.

Cite this